Research
Hormonal
Intravenous n-3 fatty acids (fish oil emulsions) reduce inflammation and improve outcomes in critically ill patients, including reduced infection rates and shorter hospital stays.
In hospital settings for critically ill patients, intravenous fish oil is used to modulate the severe inflammatory response. Evidence suggests it can help reduce infections and shorten the time patients spend in the hospital or on ventilators.
ModerateSupportsMEDIUM confidence
Intravenous n-3 fatty acids may have benefits in critically ill patients through reduced inflammation... Meta-analyses of studies of intravenous fish oil in critically ill patients are generally supportive... fish oil-containing lipid emulsions may be associated with a reduction in infections and also could be associated with a reduction in duration of ventilation and hospital length of stay
Why this rating
Meta-analyses are supportive but note inconsistencies.
Source
Omega-3 fatty acids and inflammatory processes: from molecules to man
Philip C. Calder · Biochemical Society Transactions · 2017
DOI 10.1042/bst20160474
narrative_reviewCited 1,314×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Supplementation with EPA and DHA (2.7 g/day EPA) reduces the production of pro-inflammatory eicosanoids (like PGE2) and cytokines (TNF-alpha, IL-1beta) by altering cell membrane phospholipid composition and inhibiting NF-kB activation.Good
- EPA and DHA stabilize atherosclerotic plaques by reducing macrophage infiltration and matrix metalloproteinase (MMP) expression, thereby lowering the risk of plaque rupture.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →